A Work-Out with {MS} MULTIPLE SCLEROSIS
THIS IS A WORK OUT FOR THOSE OF US WITH ILLNESS #39;...IF YOU #39;D LIKE TO LOSE SOME WEIGHT AND/OR TIGHTEN UP....TRY THESE FEW STEPS. FOLLOW US @ DEONTRA77 -----YOUTUBE SENE77-------------TWITTER SENE POINDEXTER---FACEBOOK TONGUEFUTALK.COMFrom:Danyale SeneViews:0 2ratingsTime:21:27More inEntertainment
Excerpt from:
A Work-Out with {MS} MULTIPLE SCLEROSIS - Video
Alchemedical.com: Multiple Sclerosis, Crohn #39;s, Low Dose Naltrexone
Alchemedical.com Nutriwiki.infoFrom:Alex KimViews:0 0ratingsTime:10:01More inPeople Blogs
See original here:
Alchemedical.com: Multiple Sclerosis, Crohn's, Low Dose Naltrexone - Video
MEDIAssistant MM40 Environmental Control Unit (ECU) - Hi Def
A High Definition introduction to the MEDIAssistant MM40 Environmental Control Unit (ECU) / Electronic Aid to Daily Living (EADL) for individuals with mobility limitations due to Spinal Cord Injury, Stroke, Burns, Amputation, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Cerebral Palsy and Muscular Dystrophy. The MM40 uses infrared and Insteon signals to help its user regain control of the electrical and electronic devices in the home and office. It can be operated by touch, voice control, head tracking and switch scanning. The MEDIAssistant MM40 from Convergence Concepts provides unmatched flexibility and power to help people regain control! For more information, check out http://www.ConvergenceConcepts.com or contact us at info@ConvergenceConcepts.com.From:ConvergenceConceptsViews:6 0ratingsTime:08:13More inScience Technology
See original here:
MEDIAssistant MM40 Environmental Control Unit (ECU) - Hi Def - Video
The SPYONvegas 2012 Best Man Competition
SPYONvegas #39; The Best Man returned for its second year in 2012 in partnership with Bombay Sapphire, Élevée, and Vegas/Rated. Over the course of 6 weeks, The Best Man featured four events starting with the launch at Lily Bar and Lounge, followed by Blue Martini, NOVE and the finale at The Bank Nightclub. The support of each of the contestants and charities, each winner maxed out their votes to have a total of $7000 donated. The winners from each category were: Boy Next Door: Thomas Stemmle -- Children #39;s Heart Foundation Talented: Tony Moreno -- Nevada SPCA Hero: Dana Richardson - National Multiple Sclerosis Society Socialite: Pasquale Romano -- Leukemia and Lymphoma Society Heartbreaker: Jung Kim -- "I have a Dream" Foundation Capitalist: Ryan Hamilton -- Keep Memory Alive Rebel: Dana Anderson -- The Push Forward Skate Mentor Program See more photos at http://www.spyonvegas.com Shot cut by Shoot to Kill Media http://www.shoottokillmedia.comFrom:spyonViews:21 2ratingsTime:02:57More inMusic
Multiple Sclerosis: Goldberg Clinic Patient Inteview
The Goldberg Clinic in Atlanta, Georgia has been highly successful in helping reverse rheumatoid diseases and other chronic health problems for patients from across the United States for over thirty years. Dr. Goldberg utilizes a unique, comprehensive, individualized, approach developed from his own rheumatoid disease experience, many years of clinical practice and serving as a University Professor of Rheumatology, Gastroenterology and Nutrition. A t the Goldberg Clinic, Clinical Epidemiology, Nutrition and Biological Medicine are skillfully employed to focus in on the root causes of each patient #39;s condition. It is by addressing the individual causes of disease in each person, rather than treating the symptoms, that patients with rheumatoid and other chronic illnesses are able to experience a level of health restoration few thought would ever be possible.From:TheGoldbergClinicViews:0 0ratingsTime:06:14More inScience Technology
See more here:
Multiple Sclerosis: Goldberg Clinic Patient Inteview - Video
Azad #39;s Club Car Show Timelapse for Multiple Sclerosis Check description HD
From:Azad Fatih ÖzkutluViews:0 0ratingsTime:03:03More inFilm Animation
Read the original here:
Azad's Club Car Show Timelapse for Multiple Sclerosis Check description HD - Video
This Story May Be Contagious, It #39;s Gotta Be
Atom Willis- Modern Day Hippie was never supposed to exist but life gave my sister multiple sclerosis and this is me screaming for help as the disease is in early onset and money moves mountains, it flames the fires of researchers to stay up all night. When it is taken away you get no cures. Footage from one of the last legal flash mob #39;s at the capitol. It is now a felony to hold a sign anywhere there (may or may not be) secret service. (HR 347) The events surrounding this moving art exhibit are currently being turned into a documentary film.From:wearedreaming1Views:0 0ratingsTime:04:49More inNonprofits Activism
Read more:
This Story May Be Contagious, It's Gotta Be - Video
workin #39; out with MS...Multiple Sclerosis watching the Stephanie Miller Show
working out while watching the stephanie miller show... follow tonguefutalk.com sene poindexter on fbFrom:Danyale SeneViews:0 1ratingsTime:16:46More inEntertainment
Read more here:
workin' out with MS...Multiple Sclerosis watching the Stephanie Miller Show - Video
Back Pain and Multiple Sclerosis.
Back Pain and Multiple Sclerosis lower Back Pain and Multiple Sclerosis servere Back Pain and Multiple Sclerosis upper Back Pain and Multiple SclerosisFrom:tess gutierrexViews:0 0ratingsTime:04:23More inHowto Style
Continued here:
Back Pain and Multiple Sclerosis. - Video
Best Docs Network Dallas Fort Worth October 28 2012
Best Docs Network Dallas Fort Worth is an up-beat medical TV show which features some of the best doctors in the DFW area. It airs Sundays at 10:00am on the CW33. This week #39;s lineup includes: Dr. Patrick Allen Private Practice, OB/GYN Female Hormone Therapy Dr. Clay Cockerell Dermpath Diagnostics Importance of Hygiene Dr. Freg Ghali Pediatric Dermatology of North Texas CLn Bodywash Dr. Richard Honaker Family Medicine Associates of Texas Medical Minute: Signs of a Heart Attack Dr. Glenn Ihde Ihde Surgical Group GERD Evaluation, Yolanda #39;s Story The LifeWorks Group Mental Health Overview of The Lifeworks Group Program Dr. Robert Myles PAMA, Inc. Back Pain II Dr. AL Shaw PAMA, Inc. Lyme Disease Dr. Ed Singleton PAMA, Inc. Endoscopic Foot Surgery Dr. Rebecca Stachniak Brain Spine Center of Texas Brain Tumor Dr. Supriya Thirunarayanan North Texas Institute of Neurology Headache Multiple SclerosisFrom:BestDocsNetworkViews:2 0ratingsTime:29:31More inScience Technology
Read more from the original source:
Best Docs Network Dallas Fort Worth October 28 2012 - Video
Drug #39;effective treatment for multiple sclerosis #39;
A drug which is said to "reboot" the immune system has been shown to be an effective treatment for multiple sclerosis (MS), a study has found. Doug Brown, Head of Biomedical Research at MS Society, talks to ITV News #39; Medical Editor Lawrence McGinty.From:ITVNewsViews:1 0ratingsTime:03:28More inNews Politics
Follow this link:
Drug 'effective treatment for multiple sclerosis' - Video
Iranian patients suffer most from sanctions
DesiGirlsNetwork.Blogspot.com http Updates World News Plz Subscrib for Latest World News Desperately waiting for life-saving medications; this is the fate of many Iranian patients, whose lives are at stake due to the shortage of medicines resulting from the unilateral sanctions by the US and European Union against Iran over its civilian nuclear energy program. Although the West #39;s sanctions do not directly ban the sales of medicines to Iran, they block every financial route needed to obtain drugs for patients suffering from diseases like diabetes, kidney failure, hemophilia, multiple sclerosis, thalassemia and leukemia. Saman Kojouri, Press TV, Tehran Follow our Facebook on: http://www.facebook.com Follow our Twitter on: twitter.com Follow our Tumblr on: presstvchannel.tumblr.comFrom:UpdatesWorldNewsViews:0 0ratingsTime:03:34More inNews Politics
Read more:
Iranian patients suffer most from sanctions - Video
Tom Wallisch Walks For MS
X Games champ Tom Wallisch takes to the streets to promote awareness for multiple sclerosis. Wallisch takes part in the Salt Lake City MS Walk in his ski boots.From:USSANetworkViews:1 0ratingsTime:02:26More inSports
Excerpt from:
Tom Wallisch Walks For MS - Video
The defining element of Adam Gottschalks life today is that he has multiple sclerosis. This wasnt always the case. He lived a more-or-less-normal life for a while, even after his diagnosis, but like most people with M.S., he was always bracing for the next relapse of partial paralysis or numbness or vision failure or any of the other attacks the disease unleashes unpredictably on the nervous system. Thirteen years after his diagnosis, Adam is now a case study of the degeneration that eventually occurs in everyone who gets M.S. He is only 42, but his physical capabilities are like those of an 80-year-old. His hands tremble, he walks with difficulty and his speech is labored and halting.
Adam Gottschalk, left, who has M.S., and his older brother, Chris, a neuorologist, have differing opinions on a treatment Adam received.
Dr. Paolo Zamboni
For a time in the early 1990s, Gottschalk busked outside the Shinjuku subway station in Tokyo, playing Dylan and Beatles songs, and of all the things M.S. robbed him of, its the ability to play guitar that he longs for the most. I miss that part of myself, he told me when we met at his home last winter. Because he cant drive, Gottschalk spends most of his time inside his single-story house north of Tampa, Fla. He works part time operating a natural-perfume business, writes plays and poems, listens to obscure music at high volume and smokes a lot of pot (he says marijuana helps with the chronic pain thats one of M.S.s more baffling symptoms). Several times a day Gottschalk takes five different drugs: one to keep his M.S. from getting even worse, three for his seizures and an antidepressant that helps him sleep. Dietary supplements cover the buffet in his dining room.
In the last couple of decades, nine new drugs have come on the market to treat M.S.; at least four more are currently being tested on humans. Few diseases have seen such radical transformation of treatment options in such a short time. Yet for all the new options, many of the 2.1 million people worldwide afflicted with the disease (400,000 of them in the United States) have not seen improvements, and some M.S. patients find that the adverse reactions from the drugs arent worth the benefits.
Gottschalks neurologist started him on the M.S. drug Copaxone in 2000, but he had a relapse a few years later. So Gottschalk started taking Rebif, giving himself two shots a week until the drugs side effects severe flulike symptoms for 24 hours became too much to bear. Next, about once a month for five years, Gottschalk was given an infusion of Tysabri, an even newer M.S. drug. A rare side effect landed him in the hospital in 2010 and almost killed him.
Surfing Facebook one day shortly after the Tysabri scare, Gottschalk learned that an Italian vascular surgeon named Paolo Zamboni had hypothesized that the real cause of M.S. was something called chronic cerebrospinal venous insufficiency, or CCSVI. For decades, doctors have been confident that M.S. comes about because the immune system attacks the brain, though they dont know why it does so. Zamboni contended instead that blocked veins prevent blood from draining from the head, causing iron to back up in the brain and damage nerves that send messages to the body.
Zambonis first study, published in 2009 in a small neurological journal, purported to find CCSVI in 100 percent of M.S. sufferers at one stage of the disease, and he developed a surgical procedure to treat it: opening the veins that carry blood away from the head with the aim of restoring normal blood flow. This would be done by inflating a small balloon inside the vein to widen the passage, and in rare instances by placing a device to keep it open (as is commonly performed in the arteries of patients with heart disease). Zambonis study was small, just 65 subjects, and though he had compared them with a control group, he knew which patients had M.S. and which did not. But news of CCSVI traveled quickly, and M.S. patients started seeking diagnostic procedures to see if they had CCSVI, as well as the surgery to treat it.
This article has been revised to reflect the following correction:
Correction: October 29, 2012
Read more here:
A Controversial ‘Cure’ for Multiple Sclerosis
COLUMBIA - Downtown shoppers were able to shop and donate money to a good cause on Wednesday night.
A benefit for multiple sclerosis awareness and prevention was held at Tallulah's on Wednesday. The "Shop 'n Sip" event offered wine and appetizers after a donation of $10. The proceeds will go directly to the National Multiple Sclerosis Society and Multiple Sclerosis Society of Central Missouri.
Denise Falco, community development manager for the Gateway Chapter of the Multiple Sclerosis Society of Central Missouri helped put together the event, which had wine donated from the Serenity Valley Winery in Fulton.
Flaco explains that within the Gateway Chapter community, 6,800 citizens are currently living with multiple sclerosis. This event will raise money for service resources and benefits for these community members, some of which reside in Columbia. The Gateway Chapter currently helps raise money for people with the disease in 90 counties, both in Illinois and Missouri.
"It's always nice to see Columbia citizens come out to support our cause. Every dollar counts for what we are trying to achieve for local citizens battling the disease," said Falco.
The Multiple Sclerosis Society of Central Missouri is scheduling four walks and one 5K next spring to raise more money for the local Gateway Chapter for multiple sclerosis.
Read the original:
Multiple Sclerosis Fundraiser Held at Tallulah's
10/31/2012
The society said the decision to donate was motivated by the diagnosis of a family member.
When Josh and Sacha McGraw of Ponte Vedra learned their 28-year-old daughter, Erin, had been diagnosed with MS they wanted to help, but they werent sure how, said a news release.
The release said Josh McGraw consulted with his brother Robin, who already was involved with the society through participating in Bike MS and as trustee of the Greater New England Chapter.
The brothers knew they had to take a significant leadership role with their own resources and at the same time they wanted to motivate more people to join the MS movement, said the release.
When we read about the NOW Campaign, it seemed the society was focused and understood how every dollar could be used as efficiently as possible, Josh McGraw said in the release.
The McGraws decided to leverage their family foundation, the Donald C. McGraw Foundation, to donate $1 million to the MS NOW Campaign. Robin McGraw accepted a role on the MS NOW Cabinet, and has been traveling across the country speaking to prospective donors to raise support for the campaign.
The family also has engaged in area chapter
activities, from educational conferences, to annual fundraisers.
Last month, Josh, Robin and Erins brother Casey teamed up for the Bike MS: PGA TOUR Cycle to the Shore fundraiser, riding as Team Erin.
Here is the original post:
McGraw Foundation donates $1 million to National Multiple Sclerosis Society
DUBLIN (Reuters) - Irish drugmaker Elan Corp Plc said third-quarter revenue rose by 10 percent as sales of its multiple sclerosis (MS) drug grew.
Tysabri sales, the blockbuster multiple sclerosis drug it co-markets with Biogen Idec, grew 3 percent to $403.8 million, while the number of patients rose 13 percent.
Elan relies on Tysabri for the bulk of its earnings following the failure of bapineuzumab, one of the most anticipated experimental drugs for Alzheimer's disease being developed with Johnson & Johnson and Pfizer.
Elan said third-quarter revenue rose to $306.6 million from $279.4 million a year ago, in line with the $307 million forecast by 12 analysts in a poll supplied by the company.
The company repeated its full-year guidance of adjusted EBITDA of more than $200 million.
The Dublin-based company, in which U.S. group Johnson & Johnson is an 18 percent shareholder, said in August it would spin off its Neotope drug discovery business platform as a separate public company.
After the spin-off, Elan expects earnings before interest, tax, depreciation and amortization (EBITDA) to nearly double from 2012 to more than $400 million in 2013 and $1.00 earnings per share (EPS) by 2015.
Elan said the restructuring would be completed by the end of 2012.
The company's adjusted EBITDA increased 38 percent to $67.6 million, against a consensus of $50.2 million.
(Reporting by Lorraine Turner; Editing by Louise Heavens)
Go here to read the rest:
Elan on track as multiple sclerosis drug sales rise
(Reuters) - Biotechnology company Biogen Idec Inc said U.S. health regulators extended by three months the review date of its much-awaited multiple sclerosis (MS) drug BG-12, but analysts said the delay was only a minor setback.
Shares of Biogen were down 2 percent at $150.72 in morning trading on the Nasdaq.
The stock has risen more than 50 percent over the past 12 months, largely on optimism about BG-12, which showed robust results in trials and had no safety concerns.
Analysts said the delay would push the review date to March, but added such extensions were not uncommon.
"The registrational studies for BG-12 - DEFINE and CONFIRM - enrolled about 1,200 and 1,400 patients, respectively. Given the size and complexity of the filings, we are not surprised that the FDA would require additional time to review the application," Barclays Capital analyst Anthony Butler said.
The U.S. Food and Drug Administration said it needed additional time to review the application, but did not ask for additional studies, according to Biogen.
Butler and Wells Fargo Securities analyst Brian Abrahams pointed out that Sanofi's oral MS drug Aubagio also had its review extended earlier this year, but was later approved.
BG-12, also known as dimethyl fumarate, would be the second oral MS drug on the market, competing with Novartis AG's Gilenya.
Analysts expect sales of $390 million and $980 million for BG-12 in 2013 and 2014, Barclays's Butler said in a note.
The oral drug is currently also under regulatory review in the European Union, Australia, Canada and Switzerland.
View post:
FDA extends review of Biogen's multiple sclerosis drug
ScienceDaily (Oct. 31, 2012) Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.
The discovery could have major implications for multiple sclerosis, complications from premature birth and other disorders and diseases caused by demyelination -- a process where the insulation-like sheath surrounding nerve cells in the brain becomes damaged or destroyed. Demyelination disrupts the ability of nerve cells to communicate with each other, and produces a range of motor, sensory and cognitive problems in MS and other disorders.
The study was published this week in the online edition of the Annals of Neurology. The study was conducted by a team of researchers led by Larry Sherman, Ph.D., who is a professor of cell and development biology at OHSU and a senior scientist in the Division of Neuroscience at the Oregon National Primate Research Center.
"What this means is that we have identified a whole new target for drugs that might promote repair of the damaged brain in any disorder in which demyelination occurs," Sherman said. "Any kind of therapy that can promote remyelination could be an absolute life-changer for the millions of people suffering from MS and other related disorders."
Sherman's lab has been studying MS and other conditions where myelin is damaged for more than 14 years. In 2005, he and his research team discovered that a sugar molecule, called hyaluronic acid, accumulates in areas of damage in the brains of humans and animals with demyelinating brain and spinal cord lesions. Their findings at the time, published in Nature Medicine, suggested that hyaluronic acid itself prevented remyelination by preventing cells that form myelin from differentiating in areas of brain damage.
The new study shows that the hyaluronic acid itself does not prevent the differentiation of myelin-forming cells. Rather, breakdown products generated by a specific enzyme that chews up hyaluronic acid -- called a hyaluronidase -- contribute to the remyelination failure.
This enzyme is highly elevated in MS patient brain lesions and in the nervous systems of animals with an MS-like disease. The research team, which included OHSU pediatric neurologist Stephen Back, M.D., and OHSU neuroscientist Steve Matsumoto, Ph.D., found that by blocking hyaluronidase activity, they could promote myelin-forming cell differentiation and remyelination in the mice with the MS-like disease. Most significantly, the drug that blocked hyaluronidase activity led to improved nerve cell function.
The next step is to develop drugs that specifically target this enzyme. "The drugs we used in this study could not be used to treat patients because of the serious side effects they might cause," said Sherman. "If we can block the specific enzyme that is contributing to remyelination failure in the nervous system, it would likely cause few, if any, side effects."
Sherman and other researchers at the ONPRC are uniquely positioned to test newly developed drugs for their safety and effectiveness in nonhuman primates at ONPRC that spontaneously develop an MS-like disease. If they find a drug that is effective in these monkeys, they will be in a good position to test such drugs in patients.
Sherman cautioned that the discovery does not necessarily signal a cure for MS. Many other factors can contribute to the problems associated MS and other demyelinating diseases, he said. But discovering the actions of this enzyme -- and finding a way to block it -- "could at the very least lead to new ways to promote the repair of brain and spinal cord damage either by targeting this enzyme alone or by inhibiting the enzyme in conjunction with other therapies."
The rest is here:
Potential way to repair brain damage in multiple sclerosis
Public release date: 31-Oct-2012 [ | E-mail | Share ]
Contact: Todd Murphy murphyt@ohsu.edu 503-494-8231 Oregon Health & Science University
PORTLAND, Ore. Researchers at Oregon Health & Science University have discovered that blocking a certain enzyme in the brain can help repair the brain damage associated with multiple sclerosis and a range of other neurological disorders.
The discovery could have major implications for multiple sclerosis, complications from premature birth and other disorders and diseases caused by demyelination a process where the insulation-like sheath surrounding nerve cells in the brain becomes damaged or destroyed. Demyelination disrupts the ability of nerve cells to communicate with each other, and produces a range of motor, sensory and cognitive problems in MS and other disorders.
The study was published this week in the online edition of the Annals of Neurology. The study was conducted by a team of researchers led by Larry Sherman, Ph.D., who is a professor of cell and development biology at OHSU and a senior scientist in the Division of Neuroscience at the Oregon National Primate Research Center.
"What this means is that we have identified a whole new target for drugs that might promote repair of the damaged brain in any disorder in which demyelination occurs," Sherman said. "Any kind of therapy that can promote remyelination could be an absolute life-changer for the millions of people suffering from MS and other related disorders."
Sherman's lab has been studying MS and other conditions where myelin is damaged for more than 14 years. In 2005, he and his research team discovered that a sugar molecule, called hyaluronic acid, accumulates in areas of damage in the brains of humans and animals with demyelinating brain and spinal cord lesions. Their findings at the time, published in Nature Medicine, suggested that hyaluronic acid itself prevented remyelination by preventing cells that form myelin from differentiating in areas of brain damage.
The new study shows that the hyaluronic acid itself does not prevent the differentiation of myelin-forming cells. Rather, breakdown products generated by a specific enzyme that chews up hyaluronic acid called a hyaluronidase contribute to the remyelination failure.
This enzyme is highly elevated in MS patient brain lesions and in the nervous systems of animals with an MS-like disease. The research team, which included OHSU pediatric neurologist Stephen Back, M.D., and OHSU neuroscientist Steve Matsumoto, Ph.D., found that by blocking hyaluronidase activity, they could promote myelin-forming cell differentiation and remyelination in the mice with the MS-like disease. Most significantly, the drug that blocked hyaluronidase activity led to improved nerve cell function.
The next step is to develop drugs that specifically target this enzyme. "The drugs we used in this study could not be used to treat patients because of the serious side effects they might cause," said Sherman. "If we can block the specific enzyme that is contributing to remyelination failure in the nervous system, it would likely cause few, if any, side effects."
See more here:
OHSU researchers discover potential way to repair brain damage in multiple sclerosis